MMP9 and neoplasm: Hypothesizing that MMP-9 inhibition in conjunction with standard chemotherapy with cytarabine (ara-C) may reduce the tumor load more efficiently than ara-C alone, we revealed a trend toward a reduced tumor burden by the MMP-9 inhibitor alone and a significant reduction of the tumor burden by ara-C alone or ara-C in combination with the MMP-9 inhibitor in peripheral blood (Fig. S10A), BM (Fig. S10B), and spleen (Fig. S10C), but not in lung (Fig. S10D).